Name: FOI 24/307 All Yellow Card reports for COVID-19 Pfizer-BioNTech vaccine (Batch EN1185)

Report Run Date: 23-Apr-2024

Data Lock Date: 22-Apr-2024 18:30:03

Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1

FOI 24/307 All Yellow FOI 24/307 All UK spontaneous Yellow card reports

Card reports for COVID-19 Pfizer-BioNTech vaccine (batch COVID-19 Pfizer- EN1185) received up until 15/04/2024

COVID-19 Pfizer-BioNTech vaccine (Batch EN1185):

Name: FOI 24/307 All Yellow Card reports for COVID-19 Pfizer-BioNTech vaccine (Batch EN1185)

Report Run Date: 23-Apr-2024 Data Lock Date: 22-Apr-2024 18:30:03
Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1

| Reaction Name | Total | Fatal |
|--------------------------------|-------|-------|
| Blood disorders | | |
| Anaemias NEC | | |
| Anaemia | 5 | 0 |
| Anaemias haemolytic NEC | | |
| Haemolytic anaemia | 1 | 0 |
| Coagulopathies | | |
| Coagulopathy | 1 | 0 |
| Haematological disorders | | |
| Mast cell activation syndrome | 1 | 0 |
| Leukopenias NEC | | |
| Leukopenia | 1 | 0 |
| Lymphatic system disorders NEC | | |
| Lymph node pain | 14 | 0 |
| Lymphadenitis | 1 | 0 |
| Lymphadenopathy | 81 | 0 |
| Spleen disorders | | |
| Splenic vein thrombosis | 1 | 0 |
| Thrombocytopenias | | |
| Immune thrombocytopenia | 3 | 0 |
| Thrombocytopenia | 4 | 0 |
| Blood disorders SOC TOTAL | 113 | l o |

Name: FOI 24/307 All Yellow Card reports for COVID-19 Pfizer-BioNTech vaccine (Batch EN1185)

Report Run Date: 23-Apr-2024 Data Lock Date: 22-Apr-2024 18:30:03
Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1

| Reaction Name | Tota | | Fatal |
|--|------|----|-------|
| Cardiac disorders | | | |
| Cardiac conduction disorders | | | |
| Atrioventricular block | | 1 | 0 |
| Cardiac infections and inflammations NEC | | | |
| Carditis | | 1 | 0 |
| Cardiac signs and symptoms NEC | | _ | |
| Palpitations | 4 | 18 | 0 |
| Heart failures NEC | | | |
| Cardiac failure | | 2 | 0 |
| Ischaemic coronary artery disorders | | | |
| Acute myocardial infarction | | 1 | 0 |
| Angina pectoris | | 4 | 0 |
| Myocardial infarction | | 6 | 0 |
| Myocardial ischaemia | | 2 | 0 |
| Myocardial disorders NEC | | | |
| Cardiomegaly | | 2 | 1 |
| Noninfectious myocarditis | | | |
| Myocarditis | | 2 | 0 |
| Noninfectious pericarditis | | | |
| Pericarditis | | 2 | 0 |
| Pericardial disorders NEC | | | |
| Pericardial effusion | | 3 | 0 |
| Rate and rhythm disorders NEC | | | |
| Arrhythmia | | 1 | 0 |
| Cardiac flutter | | 1 | 0 |
| Extrasystoles | | 1 | 0 |
| Tachycardia | 1 | 13 | 0 |
| Supraventricular arrhythmias | | | |
| Arrhythmia supraventricular | | 1 | 0 |
| Atrial fibrillation | | 9 | 0 |
| Atrial flutter | | 1 | 0 |
| Sinus bradycardia | | 1 | 0 |
| Ventricular arrhythmias and cardiac arrest | | | |
| Ventricular tachycardia | | 1 | 0 |
| Cardiac disorders SOC TOTAL | |)3 | 1 |

Name: FOI 24/307 All Yellow Card reports for COVID-19 Pfizer-BioNTech vaccine (Batch EN1185)

Report Run Date: 23-Apr-2024 Data Lock Date: 22-Apr-2024 18:30:03
Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1

| Reaction Name | Total | Fatal |
|--------------------------------|-------|-------|
| Congenital disorders | | |
| Cerebral disorders congenital | | |
| Cerebral palsy | 1 | 0 |
| Congenital disorders SOC TOTAL | 1 | 0 |

Name: FOI 24/307 All Yellow Card reports for COVID-19 Pfizer-BioNTech vaccine (Batch EN1185)

Report Run Date: 23-Apr-2024 Data Lock Date: 22-Apr-2024 18:30:03
Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1

| Reaction Name | Total | Fatal |
|------------------------------|-------|-------|
| Ear disorders | | |
| Ear disorders NEC | | |
| Ear congestion | 1 | 0 |
| Ear discomfort | 2 | 2 0 |
| Ear pain | 13 | 0 |
| Hearing losses | | |
| Deafness | 6 | 0 |
| Deafness bilateral | | 0 |
| Deafness neurosensory | 2 | 2 0 |
| Deafness unilateral | | 0 |
| Hypoacusis | 2 | 2 0 |
| Sudden hearing loss | 2 | 2 0 |
| Hyperacusia | | |
| Hyperacusis | | 0 |
| Inner ear disorders NEC | | |
| Vestibular disorder | 2 | . 0 |
| Inner ear signs and symptoms | | |
| Tinnitus | 39 | 0 |
| Vertigo | 22 | 2 0 |
| Vertigo positional | 3 | 0 |
| Ear disorders SOC TOTAL | 97 | 'l o |

Name: FOI 24/307 All Yellow Card reports for COVID-19 Pfizer-BioNTech vaccine (Batch EN1185)

Report Run Date: 23-Apr-2024 Data Lock Date: 22-Apr-2024 18:30:03
Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1

| Reaction Name | Total | Fatal |
|---------------------------------|-------|-------|
| Endocrine disorders | | |
| Acute and chronic thyroiditis | | |
| Thyroiditis | • | 1 0 |
| Adrenal gland disorders NEC | | |
| Adrenal haemorrhage | • | 1 0 |
| Thyroid disorders NEC | | |
| Thyroid disorder | • | 1 0 |
| Thyroid hyperfunction disorders | | |
| Hyperthyroidism | 4 | 4 0 |
| Endocrine disorders SOC TOTAL | 7 | 7 0 |

Name: FOI 24/307 All Yellow Card reports for COVID-19 Pfizer-BioNTech vaccine (Batch EN1185)

Report Run Date: 23-Apr-2024 Data Lock Date: 22-Apr-2024 18:30:03
Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1

| Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1 | | |
|--|---------------|--------------|
| Reaction Name | <u> Total</u> | <u>Fatal</u> |
| Eye disorders | | |
| Choroid and vitreous structural change, deposit and degeneration | | |
| Vitreous detachment | 1 | 0 |
| Vitreous floaters | 3 | 0 |
| Conjunctival and corneal bleeding and vascular disorders | | |
| Conjunctival haemorrhage | 1 | 0 |
| Eyelid movement disorders | | |
| Eyelid ptosis | 1 | 0 |
| Iris and uveal tract infections, irritations and inflammations | | |
| Iritis | 1 | 0 |
| Uveitis | 1 | 0 |
| Lacrimation disorders | | |
| Dry eye | 6 | 0 |
| Lacrimation decreased | 1 | 0 |
| Lacrimation increased | 4 | 0 |
| Lid, lash and lacrimal infections, irritations and inflammations | | |
| Blepharitis | 1 | 0 |
| Eyelid cyst | 1 | 0 |
| Swelling of eyelid | 3 | 0 |
| Lid, lash and lacrimal structural disorders | | |
| Dermatochalasis | 1 | 0 |
| Ocular bleeding and vascular disorders NEC | | |
| Eye haemorrhage | 1 | 0 |
| Ophthalmic vein thrombosis | 1 | 0 |
| Ocular disorders NEC | | |
| Eye disorder | 1 | 0 |
| Eye oedema | 1 | 0 |
| Eye pain | 20 | 0 |
| Eye swelling | 8 | |
| Periorbital oedema | 1 | 0 |
| Periorbital swelling | 3 | |
| Ocular infections, inflammations and associated manifestations | | |
| Eye irritation | 1 | 0 |
| Eye pruritus | 3 | |
| Ocular hyperaemia | 4 | |
| Ocular nerve and muscle disorders | | |
| Eye movement disorder | 1 | 0 |
| Ophthalmoplegia | 1 | 0 |
| Ocular sensation disorders | | |
| Asthenopia | 6 | 0 |
| Foreign body sensation in eyes | 1 | 0 |
| Photophobia | 7 | 0 |
| Optic nerve bleeding and vascular disorders | | |
| Optic ischaemic neuropathy | 1 | 0 |
| Retinal bleeding and vascular disorders (excl retinopathy) | | |
| Retinal haemorrhage | 1 | 0 |
| Retinal vein occlusion | 1 | 0 |
| Retinal, choroid and vitreous infections and inflammations | | |
| Birdshot chorioretinopathy | 1 | 0 |
| Visual disorders NEC | | |
| Diplopia | 1 | 0 |
| Metamorphopsia | 1 | 0 |
| Photopsia | 5 | Ö |

Name: FOI 24/307 All Yellow Card reports for COVID-19 Pfizer-BioNTech vaccine (Batch EN1185)

Report Run Date: 23-Apr-2024 Data Lock Date: 22-Apr-2024 18:30:03
Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1

| Reaction Name | Total | Fatal |
|---|-------|-------|
| Eve disorders Eye disorders cont'd | | |
| Vision blurred | 12 | 0 |
| Visual field disorders | | |
| Visual field defect | 2 | 0 |
| Visual impairment and blindness (excl colour blindness) | | |
| Blindness | 2 | 0 |
| Blindness transient | 1 | 0 |
| Blindness unilateral | 1 | 0 |
| Visual impairment | 8 | 0 |
| Eve disorders SOC TOTAL | 122 | 0 |

Name: FOI 24/307 All Yellow Card reports for COVID-19 Pfizer-BioNTech vaccine (Batch EN1185)

Report Run Date: 23-Apr-2024 Data Lock Date: 22-Apr-2024 18:30:03
Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1

| | DRA Version: MedDRA 26.1 | |
|---|--------------------------|---------------|
| Reaction Name | Total_ | <u> Fatal</u> |
| Gastrointestinal disorders | | |
| Anal and rectal pains | | |
| Proctalgia | 1 | 0 |
| Dental disorders NEC | | |
| Teeth brittle | 1 | 0 |
| Dental pain and sensation disorders | | |
| Dental discomfort | 1 | 0 |
| Dental paraesthesia | | 0 |
| Hyperaesthesia teeth | 1 | |
| Toothache | 2 | 2 0 |
| Dental surface disorders | | |
| Tooth discolouration | 2 | 2 0 |
| Diarrhoea (excl infective) | | |
| Diarrhoea | 62 | 2 0 |
| Diverticula | | |
| Diverticulum | | 0 |
| Dyspeptic signs and symptoms | | |
| Dyspepsia | 6 | |
| Eructation | 1 | 0 |
| Flatulence, bloating and distension | | |
| Abdominal distension | 3 | |
| Flatulence | 2 | 2 0 |
| Gastric and oesophageal haemorrhages | | |
| Mallory-Weiss syndrome | | 0 |
| Gastritis (excl infective) | | |
| Gastritis | | 0 |
| Gastrointestinal and abdominal pains (excl oral a | | |
| Abdominal pain | 16 | |
| Abdominal pain upper | 31 | |
| Gastrointestinal pain | 4 | 0 |
| Gastrointestinal atonic and hypomotility disorder | | |
| Constipation | 7 | |
| Gastric dilatation | 1 | |
| Gastrooesophageal reflux disease | 4 | |
| Impaired gastric emptying | | 0 |
| Gastrointestinal disorders NEC | | |
| Functional gastrointestinal disorder | 1 | - |
| Gastrointestinal disorder | 1 | 0 |
| Gastrointestinal signs and symptoms NEC | | |
| Abdominal discomfort | 11 | |
| Dysphagia | 5 | 0 |
| Gastrointestinal spastic and hypermotility disorder | | |
| Irritable bowel syndrome | 3 | 0 |
| Gastrointestinal vascular malformations | | |
| Gastric antral vascular ectasia | 1 | 0 |
| Gastrointestinal vascular occlusion and infarction | | _ |
| Mesenteric vein thrombosis | 1 | 0 |
| Gingival disorders, signs and symptoms NEC | | |
| Gingival disorder | 1 | |
| Noninfective gingivitis | 2 | 2 0 |
| Gingival haemorrhages | | _ |
| Gingival bleeding | 1 | 0 |
| Intestinal haemorrhages | | |

Name: FOI 24/307 All Yellow Card reports for COVID-19 Pfizer-BioNTech vaccine (Batch EN1185)

Report Run Date: 23-Apr-2024 Data Lock Date: 22-Apr-2024 18:30:03
Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1

| Reaction Name | MedDRA Version: MedDRA 26.1 | Total | Fatal |
|---|-----------------------------|-------|-------|
| Gastrointestinal disorders contestinal disorders co | ont'd | | |
| Rectal haemorrhage | | 2 | 0 |
| Small intestinal haemorrhage | | 2 | 0 |
| Malabsorption syndromes | | | |
| Coeliac disease | | 1 | 0 |
| Nausea and vomiting symptoms | | | |
| Nausea | | 182 | 0 |
| Vomiting | | 53 | 0 |
| Non-site specific gastrointestinal haemorrha | ges | | |
| Haematemesis | | 1 | 0 |
| Haematochezia | | 1 | 0 |
| Upper gastrointestinal haemorrhage | | 1 | 0 |
| Oral dryness and saliva altered | | | |
| Dry mouth | | 10 | 0 |
| Lip dry | | 2 | 0 |
| Oral soft tissue disorders NEC | | | |
| Angina bullosa haemorrhagica | | 1 | 0 |
| Oral lichen planus | | 1 | 0 |
| Oral soft tissue signs and symptoms | | | |
| Hypoaesthesia oral | | 8 | 0 |
| Lip exfoliation | | 1 | 0 |
| Lip pain | | 3 | 0 |
| Oral discomfort | | 1 | 0 |
| Oral pain | | 2 | 0 |
| Paraesthesia oral | | 16 | 0 |
| Oral soft tissue swelling and oedema | | | |
| Lip swelling | | 5 | 0 |
| Mouth swelling | | 1 | 0 |
| Salivary gland disorders NEC | | | |
| Salivary gland disorder | | 1 | 0 |
| Stomatitis and ulceration | | | |
| Aphthous ulcer | | 2 | 0 |
| Mouth ulceration | | 6 | 0 |
| Tongue disorders | | | |
| Tongue disorder | | 1 | 0 |
| Tongue ulceration | | 1 | 0 |
| Tongue signs and symptoms | | | |
| Glossodynia | | 8 | 0 |
| Swollen tongue | | 10 | 0 |
| Tongue coated | | 2 | 0 |
| Tongue discomfort | | 2 | 0 |
| Tongue eruption | | 1 | 0 |
| Tongue erythema | | 1 | 0 |
| Tongue movement disturbance | | 1 | 0 |
| Gastrointestinal disorders SOC TOTAL | | 507 | 0 |

Name: FOI 24/307 All Yellow Card reports for COVID-19 Pfizer-BioNTech vaccine (Batch EN1185)

Report Run Date: 23-Apr-2024 Data Lock Date: 22-Apr-2024 18:30:03
Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1

| Earliest Reaction Date: 16-Feb-2001 | MedDRA Version: MedDRA 26.1 | | |
|---|-----------------------------|--------------|--------------|
| Reaction Name | | <u>Total</u> | <u>Fatal</u> |
| General disorders | | | |
| Administration site reactions NEC | | | |
| Administration site extravasation | | 1 | 0 |
| Administration site pain | | 1 | 0 |
| Application and instillation site reactions | | | |
| Application site burn | | 1 | 0 |
| Application site swelling | | 1 | 0 |
| Asthenic conditions | | | |
| Asthenia | | 24 | 0 |
| Chronic fatigue syndrome | | 6 | 0 |
| Fatigue | | 293 | 0 |
| Malaise | | 74 | 0 |
| Death and sudden death | | | |
| Death | | 2 | 2 |
| Febrile disorders | | | |
| Pyrexia | | 143 | 0 |
| Feelings and sensations NEC | | | |
| Chills | | 124 | 0 |
| Feeling abnormal | | 15 | 0 |
| Feeling cold | | 22 | 0 |
| Feeling drunk | | 2 | 0 |
| Feeling hot | | 9 | 0 |
| Feeling of body temperature change | | 4 | 0 |
| Hangover | | 1 | 0 |
| Thirst | | 4 | 0 |
| Gait disturbances | | | Ū |
| Gait disturbance | | 4 | 0 |
| Gait inability | | 1 | 0 |
| General signs and symptoms NEC | | | Ŭ |
| Condition aggravated | | 10 | 0 |
| Disease recurrence | | 1 | 0 |
| Illness | | 18 | 0 |
| Influenza like illness | | 32 | 0 |
| Local reaction | | 2 | 0 |
| Peripheral swelling | | 38 | 0 |
| Swelling | | 38 | 0 |
| Swelling face | | 15 | 0 |
| Inflammations | | 13 | U |
| Inflammation | | 10 | 0 |
| Injection site reactions | | 10 | U |
| Injection site reactions Injected limb mobility decreased | | 1 | 0 |
| | | - | |
| Injection site erythema | | 3 1 | 0 |
| Injection site hypoaesthesia | | | 0 |
| Injection site mass | | 5 47 | 0 |
| Injection site pain | | | 0 |
| Injection site swelling | | 6 | 0 |
| Injection site warmth | | 1 | 0 |
| Mass conditions NEC | | | ^ |
| Cyst | | 1 | 0 |
| Mass | | 1 | 0 |
| Oedema NEC | | | _ |
| Face oedema | | 1 | 0 |
| Oedema | | 2 | 0 |

Name: FOI 24/307 All Yellow Card reports for COVID-19 Pfizer-BioNTech vaccine (Batch EN1185)

Report Run Date: 23-Apr-2024 Data Lock Date: 22-Apr-2024 18:30:03
Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1

| Reaction Name | Total | Fatal |
|---|-------|-------|
| General disorders General disorders cont'd | | |
| Pain and discomfort NEC | | |
| Axillary pain | 12 | 0 |
| Chest discomfort | 23 | 0 |
| Chest pain | 37 | 0 |
| Discomfort | 4 | 0 |
| Facial discomfort | 1 | 0 |
| Facial pain | 4 | 0 |
| Pain | 99 | 0 |
| Tenderness | 5 | 0 |
| Therapeutic and nontherapeutic responses | | |
| Drug ineffective | 4 | 0 |
| No reaction on previous exposure to drug | 1 | 0 |
| Therapeutic response unexpected | 1 | 0 |
| Trophic disorders | | |
| Atrophy | 1 | 0 |
| Ulcers NEC | | |
| Ulcer | 1 | 0 |
| Vaccination site reactions | | |
| Shoulder injury related to vaccine administration | 4 | 0 |
| Vaccination site bruising | 1 | 0 |
| Vaccination site erythema | 9 | 0 |
| Vaccination site haemorrhage | 1 | 0 |
| Vaccination site induration | 1 | 0 |
| Vaccination site irritation | 1 | 0 |
| Vaccination site mass | 3 | 0 |
| Vaccination site movement impairment | 2 | 0 |
| Vaccination site pain | 27 | 0 |
| Vaccination site pruritus | 3 | 0 |
| Vaccination site swelling | 5 | 0 |
| Vaccination site warmth | 3 | 0 |
| General disorders SOC TOTAL | 1218 | 2 |

Name: FOI 24/307 All Yellow Card reports for COVID-19 Pfizer-BioNTech vaccine (Batch EN1185)

Report Run Date: 23-Apr-2024 Data Lock Date: 22-Apr-2024 18:30:03
Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1

| Reaction Name | Total | Fatal |
|--------------------------------|-------|-------|
| Hepatic disorders | | |
| Hepatic fibrosis and cirrhosis | | |
| Cirrhosis alcoholic | 1 | 0 |
| Hepatic vascular disorders | | |
| Portal vein thrombosis | 1 | 0 |
| Hepatic disorders SOC TOTAL | 2 | 0 |

Name: FOI 24/307 All Yellow Card reports for COVID-19 Pfizer-BioNTech vaccine (Batch EN1185)

Report Run Date: 23-Apr-2024 Data Lock Date: 22-Apr-2024 18:30:03
Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1

| Reaction Name | Total | Fatal |
|---|-------|-------|
| Immune system disorders | | |
| Acute and chronic sarcoidosis | | |
| Sarcoidosis | 1 | 0 |
| Allergic conditions NEC | | |
| Hypersensitivity | 15 | 0 |
| Allergies to foods, food additives, drugs and other chemicals | | |
| Drug hypersensitivity | 1 | 0 |
| Anaphylactic and anaphylactoid responses | | |
| Anaphylactic reaction | 9 | 0 |
| Atopic disorders | | |
| Seasonal allergy | 1 | 0 |
| Autoimmune disorders NEC | | |
| Autoimmune disorder | 1 | 0 |
| Immune system disorders SOC TOTAL | 28 | l o |

Name: FOI 24/307 All Yellow Card reports for COVID-19 Pfizer-BioNTech vaccine (Batch EN1185)

Report Run Date: 23-Apr-2024 Data Lock Date: 22-Apr-2024 18:30:03
Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1

| Earliest Reaction Date: 16-Feb-2001 | MedDRA Version: MedDRA 26.1 | | |
|---|-----------------------------|--------------|-------|
| Reaction Name | | <u>Total</u> | Fatal |
| Infections | | | |
| Abdominal and gastrointestinal infections | | | |
| Appendicitis | | 1 | 0 |
| Diverticulitis | | 1 | 0 |
| Bacterial infections NEC | | | |
| Cellulitis | | 2 | 0 |
| Conjunctivitis bacterial | | 1 | 0 |
| Gastrointestinal bacterial overgrowth | | 1 | 0 |
| Breast infections | | | |
| Mastitis | | 1 | 0 |
| Candida infections | | | |
| Candida infection | | 1 | 0 |
| Oral candidiasis | | 1 | 0 |
| Vulvovaginal candidiasis | | 1 | 0 |
| Central nervous system and spinal infection | ns | | |
| Encephalitis | | 1 | 0 |
| Coronavirus infections | | | |
| COVID-19 | | 18 | 0 |
| COVID-19 pneumonia | | 1 | 1 |
| Suspected COVID-19 | | 1 | 0 |
| Dental and oral soft tissue infections | | | |
| Tooth infection | | 2 | 0 |
| Ear infections | | | |
| Ear infection | | 1 | 0 |
| Labyrinthitis | | 1 | 0 |
| Epstein-Barr viral infections | | | |
| Epstein-Barr virus infection | | 1 | 0 |
| Eye and eyelid infections | | | |
| Conjunctivitis | | 3 | 0 |
| Periorbital infection | | 1 | 0 |
| Fungal infections NEC | | | |
| Fungal infection | | 1 | 0 |
| Hepatobiliary and spleen infections | | | |
| Cholecystitis infective | | 1 | 0 |
| Herpes viral infections | | | |
| Genital herpes | | 3 | 0 |
| Herpes virus infection | | 1 | 0 |
| Herpes zoster | | 36 | 0 |
| Oral herpes | | 6 | 0 |
| Varicella | | 1 | 0 |
| Infections NEC | | | Ŭ |
| Abscess | | 1 | 0 |
| Infection | | 1 | 0 |
| Localised infection | | 1 | 0 |
| Influenza viral infections | | | Ū |
| Influenza | | 20 | 0 |
| Lower respiratory tract and lung infections | | 0 | |
| Lower respiratory tract infection | | 3 | O |
| Pneumonia | | 2 | 0 |
| Sepsis, bacteraemia, viraemia and fungaei | mia NFC | | |
| Neutropenic sepsis | IIIG I TLO | 1 | C |
| Sepsis | | 2 | 0 |
| Skin structures and soft tissue infections | | | |

Name: FOI 24/307 All Yellow Card reports for COVID-19 Pfizer-BioNTech vaccine (Batch EN1185)

Report Run Date: 23-Apr-2024 Data Lock Date: 22-Apr-2024 18:30:03
Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1

| Reaction Na | me | Total | Fatal |
|-----------------|------------------------|-------|-------|
| Infections | Infections cont'd | | |
| Dermatitis i | nfected | | 1 0 |
| Pustule | | | 2 0 |
| Skin infection | on | ; | 3 0 |
| Upper respira | atory tract infections | | |
| Nasopharyı | ngitis | 1; | 3 0 |
| Rhinitis | | | 1 0 |
| Sinusitis | | | 2 0 |
| Tracheosto | my infection | | 1 0 |
| Urinary tract | infections | | |
| Cystitis | | | 2 0 |
| Kidney infe | ction | | 1 0 |
| Viral infection | ns NEC | | |
| Conjunctivi | tis viral | | 1 0 |
| Meningitis | <i>v</i> iral | | 1 0 |
| Viral infecti | on | | 1 0 |
| Viral rash | | | 2 0 |
| Infections SOC | TOTAL | 15 | 1 1 |

Name: FOI 24/307 All Yellow Card reports for COVID-19 Pfizer-BioNTech vaccine (Batch EN1185)

Report Run Date: 23-Apr-2024 Data Lock Date: 22-Apr-2024 18:30:03
Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1

| Reaction Name | Total | Fatal |
|---|-------|-------|
| Injuries | | |
| Abdominal and gastrointestinal injuries NEC | | |
| Tooth injury | 1 | 0 |
| Exposures associated with pregnancy, delivery and lactation | | |
| Exposure via breast milk | 1 | 0 |
| Foetal exposure during pregnancy | 1 | 0 |
| Maternal exposure during breast feeding | 3 | 0 |
| Maternal exposure during pregnancy | 1 | 0 |
| Eye injuries NEC | | |
| Eye injury | 1 | 0 |
| Limb fractures and dislocations | | |
| Clavicle fracture | 1 | 0 |
| Medication errors, product use errors and issues NEC | | |
| Medication error | 1 | 0 |
| Wrong drug | 1 | 0 |
| Muscle, tendon and ligament injuries | | |
| Muscle injury | 1 | 0 |
| Nerve injuries NEC | | |
| Nerve injury | 2 | 0 |
| Non-site specific injuries NEC | | |
| Electric shock | 1 | 0 |
| Fall | 2 | 0 |
| Wound secretion | 1 | 0 |
| Non-site specific procedural complications | | |
| Injection related reaction | 1 | 0 |
| Overdoses NEC | | |
| Overdose | 1 | 0 |
| Poisoning and toxicity | | |
| Alcohol poisoning | 1 | 0 |
| Product administration errors and issues | | |
| Inappropriate schedule of product administration | 5 | 0 |
| Site specific injuries NEC | | |
| Limb crushing injury | 1 | 0 |
| Skin injuries NEC | | |
| Contusion | 14 | 0 |
| Scratch | 1 | Ö |
| Vaccination related complications | | |
| Immunisation reaction | 2 | 0 |
| Injuries SOC TOTAL | 44 | |

Name: FOI 24/307 All Yellow Card reports for COVID-19 Pfizer-BioNTech vaccine (Batch EN1185)

Report Run Date: 23-Apr-2024 Data Lock Date: 22-Apr-2024 18:30:03
Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1

| Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1 | | |
|---|-------|-------|
| Reaction Name | Total | Fatal |
| Investigations | | |
| Autoimmunity analyses | | |
| Rheumatoid factor increased | 1 | 0 |
| Carbohydrate tolerance analyses (incl diabetes) | | |
| Blood glucose increased | 7 | 0 |
| Cardiac auscultatory investigations | | |
| Heart sounds abnormal | 1 | 0 |
| Cardiac imaging procedures | | |
| Magnetic resonance imaging heart | 1 | 0 |
| Coagulation and bleeding analyses | | |
| Bleeding time prolonged | 1 | 0 |
| International normalised ratio fluctuation | 1 | 0 |
| Endocrine analyses and imaging NEC | | |
| Hormone level abnormal | 1 | 0 |
| Gene analyses | | |
| EGFR status assay | 1 | 0 |
| Heart rate and pulse investigations | | |
| Heart rate | 7 | 0 |
| Heart rate abnormal | 2 | 0 |
| Heart rate decreased | 3 | 0 |
| Heart rate increased | 8 | 0 |
| Heart rate irregular | 4 | 0 |
| Pulse abnormal | 1 | 0 |
| Hepatobiliary function diagnostic procedures | | |
| Liver function test abnormal | 1 | 0 |
| Investigations NEC | | |
| Blood test | 1 | 0 |
| Blood test normal | 1 | 0 |
| Metabolism tests NEC | | |
| Blood uric acid increased | 1 | 0 |
| Mineral and electrolyte analyses | | |
| Blood iron | 1 | 0 |
| Blood sodium decreased | 1 | 0 |
| Neurologic diagnostic procedures | | |
| Lumbar puncture | 1 | 0 |
| Temperature perception test increased | 1 | 0 |
| Physical examination procedures and organ system status | _ | _ |
| Body temperature | 5 | 0 |
| Body temperature abnormal | 1 | 0 |
| Body temperature increased | 4 | 0 |
| Weight decreased | 3 | 0 |
| Weight increased | 1 | 0 |
| Platelet analyses | | |
| Platelet count decreased | 4 | 0 |
| Vascular tests NEC (incl blood pressure) | | |
| Blood pressure decreased | 1 | 0 |
| Blood pressure increased | 3 | 0 |
| Virus identification and serology | | |
| SARS-CoV-2 antibody test | 1 | 0 |
| White blood cell analyses | | |
| Lymphocyte count decreased | 1 | 0 |
| Neutrophil count | 1 | 0 |
| Neutrophil count decreased | 1 | 0 |

Name: FOI 24/307 All Yellow Card reports for COVID-19 Pfizer-BioNTech vaccine (Batch EN1185)

Report Run Date: 23-Apr-2024 Data Lock Date: 22-Apr-2024 18:30:03
Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1

| Reaction Name | | Total | Fatal |
|--------------------|-----------------------|-------|-------|
| Investigations | Investigations cont'd | | |
| Investigations SOC | TOTAL | 73 | 0 |

Name: FOI 24/307 All Yellow Card reports for COVID-19 Pfizer-BioNTech vaccine (Batch EN1185)

Report Run Date: 23-Apr-2024 Data Lock Date: 22-Apr-2024 18:30:03
Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1

| Reaction Name | Total | Fatal |
|---|-------|-------|
| Metabolic disorders | | |
| Appetite disorders | | |
| Decreased appetite | 11 | 0 |
| Hypophagia | 1 | 0 |
| Diabetes mellitus (incl subtypes) | | |
| Diabetes mellitus | 1 | 0 |
| Type 1 diabetes mellitus | 1 | 0 |
| Disorders of purine metabolism | | |
| Gout | 4 | 0 |
| Food malabsorption and intolerance syndromes (excl sugar intolerance) | | |
| Food intolerance | 1 | 0 |
| Histamine intolerance | 1 | 0 |
| General nutritional disorders NEC | | |
| Abnormal loss of weight | 5 | 0 |
| Abnormal weight gain | 1 | 0 |
| Food aversion | 1 | 0 |
| Hyperglycaemic conditions NEC | | |
| Hyperglycaemia | 5 | 0 |
| Hypoglycaemic conditions NEC | | |
| Hypoglycaemia | 3 | 0 |
| Sugar intolerance (excl glucose intolerance) | | |
| Lactose intolerance | 1 | 0 |
| Total fluid volume decreased | | |
| Dehydration | 5 | 0 |
| Metabolic disorders SOC TOTAL | 41 | 0 |

Name: FOI 24/307 All Yellow Card reports for COVID-19 Pfizer-BioNTech vaccine (Batch EN1185)

Report Run Date: 23-Apr-2024 Data Lock Date: 22-Apr-2024 18:30:03
Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1

| | MedDRA Version: MedDRA 26.1 | |
|---|-----------------------------|-------|
| Reaction Name | Total | Fatal |
| Muscle & tissue disorders | | |
| Arthropathies NEC | | |
| Arthritis | 9 | |
| Autoimmune arthritis | 1 | 0 |
| Bone related signs and symptoms | | |
| Bone pain | 6 | |
| Bone swelling | 1 | - |
| Pain in jaw | 2 2 | 0 |
| Spinal pain | 2 | 0 |
| Bursal disorders | | |
| Bursitis | 1 | 0 |
| Connective tissue disorders NEC | | |
| Polymyalgia rheumatica | 4 | |
| Sjogren's syndrome | 1 | 0 |
| Joint related disorders NEC | | |
| Joint lock | 2 | 0 |
| Periarthritis | 7 | 0 |
| Joint related signs and symptoms | | |
| Arthralgia | 166 | |
| Joint noise | 1 | 0 |
| Joint stiffness | 5 | |
| Joint swelling | 16 | 0 |
| Lupus erythematosus (incl subtypes) | | |
| Systemic lupus erythematosus | 2 | 0 |
| Muscle infections and inflammations | | |
| Myositis | 2 | 0 |
| Muscle pains | | |
| Fibromyalgia | 1 | 0 |
| Myalgia | 142 | 0 |
| Muscle related signs and symptoms NEC | | |
| Muscle atrophy | 1 | 0 |
| Muscle discomfort | 1 | 0 |
| Muscle fatigue | 4 | |
| Muscle spasms | 21 | 0 |
| Muscle tightness | 2 | |
| Muscle twitching | 6 | 0 |
| Muscle weakness conditions | | _ |
| Muscular weakness | 16 | 0 |
| Musculoskeletal and connective tissue conditi | ons NEC | |
| Limb mass | 1 | 0 |
| Musculoskeletal stiffness | 24 | |
| Sacroiliac joint dysfunction | 1 | 0 |
| Musculoskeletal and connective tissue pain a | | |
| Back pain | 30 | |
| Limb discomfort | 15 | |
| Musculoskeletal chest pain | | 0 |
| Musculoskeletal discomfort | 2 | |
| Musculoskeletal pain | 3 | |
| Neck pain | 23 | |
| Pain in extremity | 182 | 0 |
| Osteoarthropathies | | _ |
| Osteoarthritis | 4 | 0 |
| Psoriatic arthropathies | | |

Name: FOI 24/307 All Yellow Card reports for COVID-19 Pfizer-BioNTech vaccine (Batch EN1185)

Report Run Date: 23-Apr-2024 Data Lock Date: 22-Apr-2024 18:30:03 Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1

| Reaction Name | Total | Fatal |
|---|-------|-------|
| Muscle & tissue disorders e & tissue disorders cont'd | | |
| Psoriatic arthropathy | 1 | 0 |
| Rheumatoid arthropathies | | |
| Rheumatoid arthritis | 3 | 0 |
| Soft tissue disorders NEC | | |
| Axillary mass | 4 | 0 |
| Groin pain | 2 | 0 |
| Spine and neck deformities | | |
| Kyphosis | 1 | 0 |
| Spondyloarthropathies | | |
| Ankylosing spondylitis | 2 | 0 |
| Arthritis reactive | 1 | 0 |
| Synovial disorders | | |
| Synovial cyst | 1 | 0 |
| Tendon disorders | | |
| Posterior tibial tendon dysfunction | 1 | 0 |
| Tendon pain | 1 | 0 |
| Trigger finger | 1 | 0 |
| Muscle & tissue disorders SOC TOTAL | 726 | 0 |

Name: FOI 24/307 All Yellow Card reports for COVID-19 Pfizer-BioNTech vaccine (Batch EN1185)

Report Run Date: 23-Apr-2024 Data Lock Date: 22-Apr-2024 18:30:03
Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1

| Reaction Name | Total | Fatal |
|--|-------|-------|
| Neoplasms | | |
| Follicular lymphomas | | |
| Follicular lymphoma | 1 | 0 |
| Lymphomas unspecified NEC | | |
| Lymphoma | 1 | 0 |
| Pancreatic neoplasms malignant (excl islet cell and carcinoid) | | |
| Pancreatic carcinoma | 1 | 0 |
| Skin melanomas (excl ocular) | | |
| Malignant melanoma | 1 | 0 |
| Skin neoplasms malignant and unspecified (excl melanoma) | | |
| Basal cell carcinoma | 1 | 0 |
| Neoplasms SOC TOTAL | 5 | l o |

Name: FOI 24/307 All Yellow Card reports for COVID-19 Pfizer-BioNTech vaccine (Batch EN1185)

Report Run Date: 23-Apr-2024 Data Lock Date: 22-Apr-2024 18:30:03
Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1

| Earliest Reaction Date: 16-Feb-2001 | MedDRA Version: MedDRA 26.1 | | |
|--------------------------------------|----------------------------------|--------------|--------------|
| Reaction Name | | <u>Total</u> | <u>Fatal</u> |
| Nervous system disorders | | | |
| Absence seizures | | | |
| Petit mal epilepsy | | 1 | 0 |
| Central nervous system haemorrhage | es and cerebrovascular accidents | | |
| Cerebellar infarction | | 1 | 0 |
| Cerebral haemorrhage | | 1 | 0 |
| Cerebrovascular accident | | 7 | 0 |
| Embolic stroke | | 1 | 0 |
| Ischaemic stroke | | 2 | 0 |
| Lacunar stroke | | 1 | 0 |
| Subarachnoid haemorrhage | | 1 | 0 |
| Cerebrovascular venous and sinus th | rombosis | | |
| Cerebral venous sinus thrombosis | | 2 | 0 |
| Coma states | | | |
| Coma | | 1 | 0 |
| Coordination and balance disturbance | es | | |
| Balance disorder | | 8 | 0 |
| Coordination abnormal | | 2 | 0 |
| Cortical dysfunction NEC | | | |
| Aphasia | | 2 | 0 |
| Disturbances in consciousness NEC | | | _ |
| Lethargy | | 27 | 0 |
| Loss of consciousness | | 8 | 0 |
| Postictal state | | 1 | 0 |
| Somnolence | | 12 | 0 |
| Syncope | | 18 | 0 |
| Dyskinesias and movement disorders | NEC | . 0 | Ŭ |
| Hypokinesia | | 1 | 0 |
| Psychomotor hyperactivity | | 1 | 0 |
| Eye movement disorders | | | J |
| IIIrd nerve paralysis | | 1 | 0 |
| IVth nerve paralysis | | 1 | 0 |
| Facial cranial nerve disorders | | - | _ |
| Bell's palsy | | 10 | 0 |
| Facial paralysis | | 7 | 0 |
| Facial spasm | | 2 | 0 |
| Generalised tonic-clonic seizures | | _ | Ŭ |
| Generalised tonic-clonic seizure | | 2 | 0 |
| Headaches NEC | | _ | Ŭ |
| Cluster headache | | 1 | 0 |
| Cold-stimulus headache | | 2 | 0 |
| Headache | | 322 | 0 |
| New daily persistent headache | | 1 | 0 |
| Primary stabbing headache | | 1 | 0 |
| Sinus headache | | 2 | 0 |
| Tension headache | | 5 | 0 |
| Memory loss (excl dementia) | | Ŭ | Ŭ |
| Amnesia | | 6 | 0 |
| Memory impairment | | 1 | 0 |
| Transient global amnesia | | 1 | 0 |
| Mental impairment (excl dementia and | d memory loss) | l l | U |
| Disturbance in attention | a montory today | 7 | 0 |
| | | 7 | 0 |
| Mental impairment | | 11 | 0 |

Name: FOI 24/307 All Yellow Card reports for COVID-19 Pfizer-BioNTech vaccine (Batch EN1185)

Report Run Date: 23-Apr-2024 Data Lock Date: 22-Apr-2024 18:30:03
Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1

| Earliest Reaction Date: 16-Feb-2001 | MedDRA Version: MedDRA 26.1 | | |
|--|-----------------------------|------------|-------|
| Reaction Name | <u>To</u> | <u>tal</u> | Fatal |
| Nervous system disorders us system disorders co | nt'd | | |
| Migraine headaches | | | |
| Migraine | | 34 | 0 |
| Migraine with aura | | 6 | 0 |
| Retinal migraine | | 1 | 0 |
| Mononeuropathies | | | |
| Nerve compression | | 1 | 0 |
| Multiple sclerosis acute and progressive | | | |
| Multiple sclerosis | | 2 | 0 |
| Multiple sclerosis relapse | | 1 | 0 |
| Muscle tone abnormal | | | |
| Hypotonia | | 1 | 0 |
| Narcolepsy and hypersomnia | | | |
| Hypersomnia | | 4 | 0 |
| Nervous system disorders NEC | | | |
| Nervous system disorder | | 2 | 0 |
| Neurologic visual problems NEC | | | |
| Hemianopia homonymous | | 1 | 0 |
| Neurological signs and symptoms NEC | | | |
| Brain fog | | 8 | 0 |
| Dizziness | | 121 | 0 |
| Dizziness exertional | | 1 | 0 |
| Dizziness postural | | 7 | 0 |
| Head discomfort | | 4 | 0 |
| Neurological symptom | | 1 | 0 |
| Presyncope | | 5 | 0 |
| Unresponsive to stimuli | | 1 | 0 |
| Neuromuscular junction dysfunction | | · | J |
| Myasthenia gravis | | 1 | 0 |
| Olfactory nerve disorders | | | 0 |
| Anosmia | | 3 | 0 |
| Parosmia | | 4 | 0 |
| Paraesthesias and dysaesthesias | | | J |
| Burning sensation | | 8 | 0 |
| Formication | | 2 | 0 |
| Hyperaesthesia | | 1 | 0 |
| Hypoaesthesia | | 33 | 0 |
| Paraesthesia | | 66 | 0 |
| Reversed hot-cold sensation | | 1 | 0 |
| Paralysis and paresis (excl cranial nerve) | | | U |
| Monoparesis | | 2 | 0 |
| Paralysis | | 1 | 0 |
| Parkinson's disease and parkinsonism | | ' | J |
| Freezing phenomenon | | 1 | 0 |
| Parkinson's disease | | 1 | 0 |
| Peripheral neuropathies NEC | | | U |
| | | 2 | 0 |
| Neuropathy peripheral Seizures and seizure disorders NEC | | | U |
| | | 2 | ^ |
| Epilepsy Portiol soizures | | 3 | 0 |
| Partial seizures | | 7 | 0 |
| Seizure Tania canyulaian | | | 0 |
| Tonic convulsion | | 1 | 0 |
| Sensory abnormalities NEC | | | |

Name: FOI 24/307 All Yellow Card reports for COVID-19 Pfizer-BioNTech vaccine (Batch EN1185)

Report Run Date: 23-Apr-2024 Data Lock Date: 22-Apr-2024 18:30:03
Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1

| Reaction Name | Total | Fatal |
|--|-------|-------|
| Nervous system disorders gus system disorders cont'd | | |
| Ageusia | 3 | 0 |
| Dysgeusia | 13 | 0 |
| Electric shock sensation | 2 | 0 |
| Neuralgia | 9 | 0 |
| Post herpetic neuralgia | 1 | 0 |
| Restless legs syndrome | 1 | 0 |
| Sensory disturbance | 3 | 0 |
| Sensory loss | 4 | 0 |
| Taste disorder | 12 | 0 |
| Speech and language abnormalities | | |
| Incoherent | 1 | 0 |
| Speech disorder | 1 | 0 |
| Transient cerebrovascular events | | |
| Transient ischaemic attack | 2 | 0 |
| Tremor (excl congenital) | | |
| Tremor | 23 | 0 |
| Trigeminal disorders | | |
| Trigeminal neuralgia | 2 | 0 |
| Nervous system disorders SOC TOTAL | 887 | 0 |

Name: FOI 24/307 All Yellow Card reports for COVID-19 Pfizer-BioNTech vaccine (Batch EN1185)

Report Run Date: 23-Apr-2024 Data Lock Date: 22-Apr-2024 18:30:03
Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1

| Reaction Name | Total | Fatal |
|--------------------------------|-------|-------|
| Pregnancy conditions | | |
| Abortions spontaneous | | |
| Abortion spontaneous | 1 | 0 |
| Pregnancy conditions SOC TOTAL | 1 | 0 |

Name: FOI 24/307 All Yellow Card reports for COVID-19 Pfizer-BioNTech vaccine (Batch EN1185)

Report Run Date: 23-Apr-2024 Data Lock Date: 22-Apr-2024 18:30:03
Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1

| Reaction Name | Total | Fatal |
|-------------------------------|-------|-------|
| Device malfunction events NEC | | |
| Thrombosis in device | 1 | 0 |
| Product physical issues | | |
| Product taste abnormal | 1 | 0 |
| Product quality issues NEC | | |
| Product complaint | 1 | 0 |
| null SOC TOTAL | 3 | 0 |

Name: FOI 24/307 All Yellow Card reports for COVID-19 Pfizer-BioNTech vaccine (Batch EN1185)

Report Run Date: 23-Apr-2024 Data Lock Date: 22-Apr-2024 18:30:03
Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1

| Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1 | | |
|---|---------------|--------------|
| Reaction Name | <u> Total</u> | <u>Fatal</u> |
| Psychiatric disorders | | |
| Anxiety symptoms | | |
| Agitation | 1 | 0 |
| Anxiety | 5 | 0 |
| Nervousness | 1 | 0 |
| Stress | 1 | 0 |
| Behaviour and socialisation disturbances | | |
| Disinhibition | 1 | 0 |
| Paranoia | 1 | 0 |
| Cognitive and attention disorders and disturbances NEC | | |
| Mental fatigue | 5 | 0 |
| Confusion and disorientation | | |
| Confusional state | 12 | 0 |
| Disorientation | 4 | l 0 |
| Deliria | | |
| Delirium | 1 | О (|
| Depressive disorders | | |
| Depression | 6 | 0 |
| Major depression | 1 | 0 |
| Disturbances in initiating and maintaining sleep | | |
| Insomnia | 13 | 0 |
| Middle insomnia | 1 | Ö |
| Emotional and mood disturbances NEC | | ľ |
| Emotional disorder | 2 | 0 |
| Emotional distress | 2 | Ö |
| Irritability | 2 | |
| Fear symptoms and phobic disorders (incl social phobia) | | |
| Phobia | 1 | 0 |
| Hallucinations (excl sleep-related) | i ' | |
| Hallucination, auditory | 1 | 0 |
| Increased physical activity levels | ' | l ' |
| Restlessness | 1 | 0 |
| Mood alterations with depressive symptoms | ' | l ' |
| Depressed mood | 4 | 0 |
| Tearfulness | 1 | |
| Mood disorders NEC | ' | ٠ ا |
| Apathy | 1 | 0 |
| Listless | 1 | |
| Panic attacks and disorders | | ٠ ا |
| Panic attack | 2 | ٨ |
| Panic attack Panic reaction | 2 | 0 0 |
| Parasomnias | | " |
| | 1 | _ ا |
| Abnormal dreams | 3 | |
| Nightmare | - ' | 0 |
| Pervasive developmental disorders NEC | 1 | |
| Autism spectrum disorder | 1 | 0 |
| Sleep disorders NEC | _ | _ |
| Sleep disorder | 6 | 0 |
| Somatic symptom disorders | _ | _ |
| Conversion disorder | 3 | 0 |
| Speech articulation and rhythm disturbances | | |
| Dysphemia | 1 | 0 |
| Psychiatric disorders SOC TOTAL | 86 | 0 |

Name: FOI 24/307 All Yellow Card reports for COVID-19 Pfizer-BioNTech vaccine (Batch EN1185)

Report Run Date: 23-Apr-2024 Data Lock Date: 22-Apr-2024 18:30:03
Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1

| Reaction Name | Total | Fatal |
|--------------------------------------|-------|-------|
| Renal & urinary disorders | | |
| Bladder and urethral symptoms | | |
| Incontinence | 2 | 2 0 |
| Pollakiuria | 4 | 0 |
| Urine flow decreased | 1 | 0 |
| Myoneurogenic bladder disorders | | |
| Bladder dysfunction | 1 | 0 |
| Renal failure and impairment | | |
| Chronic kidney disease | 1 | 0 |
| Renal failure | | 0 |
| Renal impairment | 1 | 0 |
| Urinary tract signs and symptoms NEC | | |
| Haemorrhage urinary tract | 1 | 0 |
| Renal pain | | 0 |
| Renal & urinary disorders SOC TOTAL | 16 | o l |

Name: FOI 24/307 All Yellow Card reports for COVID-19 Pfizer-BioNTech vaccine (Batch EN1185)

Report Run Date: 23-Apr-2024 Data Lock Date: 22-Apr-2024 18:30:03
Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1

| Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1 | | |
|---|---------------|--------------|
| Reaction Name | <u> Total</u> | <u>Fatal</u> |
| Reproductive & breast disorders | | |
| Breast signs and symptoms | | |
| Breast pain | 3 | 0 |
| Breast swelling | 1 | 0 |
| Cervix disorders NEC | | |
| Cervix disorder | 1 | 0 |
| Erection and ejaculation conditions and disorders | | |
| Erectile dysfunction | 2 | 0 |
| Lactation disorders | | |
| Galactorrhoea | 1 | 0 |
| Menopausal effects NEC | | |
| Menopausal symptoms | 1 | C |
| Menopausal effects on the genitourinary tract | | |
| Postmenopausal haemorrhage | 1 | C |
| Menstruation and uterine bleeding NEC | | |
| Dysmenorrhoea | 5 | O |
| Intermenstrual bleeding | 1 | 0 |
| Menstrual discomfort | 1 | 0 |
| Menstrual disorder | 6 | 0 |
| Menstruation irregular | 11 | 0 |
| Menstruation with decreased bleeding | | |
| Amenorrhoea | 2 | 0 |
| Hypomenorrhoea | 3 | 0 |
| Menstruation delayed | 10 | 0 |
| Oligomenorrhoea | 2 | O |
| Menstruation with increased bleeding | | |
| Heavy menstrual bleeding | 14 | C |
| Polymenorrhoea | 1 | C |
| Pelvis and broad ligament disorders NEC | | |
| Pelvic haemorrhage | 1 | 0 |
| Penile disorders NEC (excl erection and ejaculation) | | |
| Penile swelling | 1 | C |
| Reproductive tract signs and symptoms NEC | | |
| Pelvic pain | 1 | C |
| Scrotal disorders NEC | | |
| Scrotal swelling | 1 | C |
| Testicular and epididymal disorders NEC | | |
| Testicular pain | 1 | O |
| Vulvovaginal disorders NEC | | |
| Vaginal haemorrhage | 6 | 0 |
| Vulvovaginal signs and symptoms | | |
| Coital bleeding | 1 | 0 |
| Reproductive & breast disorders SOC TOTAL | 78 | |

Name: FOI 24/307 All Yellow Card reports for COVID-19 Pfizer-BioNTech vaccine (Batch EN1185)

Report Run Date: 23-Apr-2024 Data Lock Date: 22-Apr-2024 18:30:03
Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1

| Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1 | | |
|---|-------|-------|
| Reaction Name | Total | Fatal |
| Respiratory disorders | | |
| Breathing abnormalities | | |
| Dyspnoea | 60 | 0 |
| Hyperventilation | 1 | 0 |
| Hypopnoea | 3 | 0 |
| Mouth breathing | 1 | 0 |
| Respiration abnormal | 1 | 0 |
| Respiratory arrest | 1 | 0 |
| Respiratory depression | 1 | 0 |
| Bronchial conditions NEC | | |
| Bronchiectasis | 1 | 0 |
| Bronchospasm and obstruction | | |
| Asthma | 4 | 0 |
| Wheezing | 9 | 0 |
| Coughing and associated symptoms | | |
| Cough | 30 | 0 |
| Productive cough | 2 | 0 |
| Laryngeal and adjacent sites disorders NEC (excl infections and | | |
| neoplasms) Vocal cord disorder | 1 | 0 |
| | 1 | 0 |
| Lower respiratory tract signs and symptoms | | 0 |
| Pleuritic pain | 3 | 0 |
| Pulmonary pain | 3 | 0 |
| Nasal congestion and inflammations | | 0 |
| Nasal congestion | 6 | 0 |
| Nasal disorders NEC | 40 | 0 |
| Epistaxis | 12 | 0 |
| Paranasal sinus disorders (excl infections and neoplasms) | | |
| Sinonasal obstruction | 2 | 0 |
| Sinus congestion | 3 | 0 |
| Parenchymal lung disorders NEC | | 0 |
| Pulmonary fibrosis | 1 | 0 |
| Pharyngeal disorders (excl infections and neoplasms) | | • |
| Pharyngeal paraesthesia | 1 | 0 |
| Pharyngeal swelling | 5 | 0 |
| Tonsillar hypertrophy | 1 | 0 |
| Pleural infections and inflammations | | |
| Pleurisy | 1 | 0 |
| Pulmonary oedemas | | |
| Pulmonary congestion | 1 | 0 |
| Pulmonary thrombotic and embolic conditions | _ | |
| Pulmonary embolism | 7 | 3 |
| Respiratory signs and symptoms NEC | 1 | 0 |
| Respiratory symptom | 1 | 0 |
| Upper respiratory tract signs and symptoms | | 0 |
| Aphonia | 2 | 0 |
| Dry throat | 3 | 0 |
| Dysphonia Oranhan in goal discomfort | 6 | 0 |
| Oropharyngeal discomfort | 2 | 0 |
| Oropharyngeal pain | 31 | 0 |
| Rhinalgia | 2 | 0 |
| Rhinorrhoea | 12 | 0 |
| Sinus pain | 2 | 0 |

Name: FOI 24/307 All Yellow Card reports for COVID-19 Pfizer-BioNTech vaccine (Batch EN1185)

Report Run Date: 23-Apr-2024 Data Lock Date: 22-Apr-2024 18:30:03
Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1

| Reaction Name | Total | Fatal |
|---|-------|-------|
| Respiratory disorders espiratory disorders cont'd | | |
| Sneezing | 9 | 0 |
| Throat irritation | 2 | 0 |
| Throat tightness | 4 | 0 |
| Upper-airway cough syndrome | 1 | 0 |
| Yawning | 2 | 0 |
| Respiratory disorders SOC TOTAL | 240 | 3 |

Name: FOI 24/307 All Yellow Card reports for COVID-19 Pfizer-BioNTech vaccine (Batch EN1185)

Report Run Date: 23-Apr-2024 Data Lock Date: 22-Apr-2024 18:30:03
Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1

| Earliest Reaction Date: 16-Feb-2001 | MedDRA Version: MedDRA 26.1 | | |
|---|-----------------------------|-------|-------|
| Reaction Name | • | Total | Fatal |
| Skin disorders | | | |
| Acnes | | | |
| Acne | | 3 | 0 |
| Alopecias | | | |
| Alopecia | | 8 | 0 |
| Alopecia areata | | 1 | 0 |
| Hypotrichosis | | 1 | 0 |
| Angioedemas | | | |
| Angioedema | | 1 | 0 |
| Apocrine and eccrine gland disorders | | | - |
| Cold sweat | | 5 | 0 |
| Hyperhidrosis | | 29 | 0 |
| Hypohidrosis | | 1 | 0 |
| Miliaria | | 1 | 0 |
| Night sweats | | 6 | 0 |
| Bullous conditions | | J | U |
| Blister | | 9 | 0 |
| Dermatitis bullous | | 1 | 0 |
| Erythema multiforme | | 1 | 0 |
| Toxic epidermal necrolysis | | 1 | 0 |
| Connective tissue disorders | | ' | U |
| | | 1 | 0 |
| Dermatomyositis | | 1 | 0 |
| Dermal and epidermal conditions NEC | | 4 | ^ |
| Dry skin Macule | | 4 | 0 |
| | | - | 0 |
| Pain of skin | | 5 | 0 |
| Sensitive skin | | 1 | 0 |
| Skin burning sensation | | 4 | 0 |
| Skin degenerative disorder | | 1 | 0 |
| Skin discolouration | | 2 | 0 |
| Skin lesion | | 1 | 0 |
| Skin reaction | | 2 | 0 |
| Skin sensitisation | | 1 | 0 |
| Skin swelling | | 1 | 0 |
| Skin tightness | | 2 | 0 |
| Skin warm | | - 1 | 0 |
| Dermatitis and eczema | | | _ |
| Dermatitis | | 2 | 0 |
| Dermatitis allergic | | 2 | 0 |
| Dermatitis atopic | | 2 | 0 |
| Eczema | | • 1 | 0 |
| Eczema asteatotic | | 1 | 0 |
| Eczema nummular | | 1 | 0 |
| Skin irritation | | 5 | 0 |
| Erythemas | | | |
| Erythema | | 28 | 0 |
| Exfoliative conditions | | | |
| Skin exfoliation | | 4 | 0 |
| Hyperkeratoses | | | |
| Lichenoid keratosis | | 1 | C |
| Hyperpigmentation disorders | | | |
| Skin hyperpigmentation | | 1 | O |
| Nail and nail bed conditions (excl infections | and infestations) | | |

Name: FOI 24/307 All Yellow Card reports for COVID-19 Pfizer-BioNTech vaccine (Batch EN1185)

Report Run Date: 23-Apr-2024 Data Lock Date: 22-Apr-2024 18:30:03
Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1

| Reaction Name | Total | Fatal |
|---|-------|-------|
| Skin disorders Skin disorders cont'd | | |
| Nail pigmentation | 1 | 0 |
| Papulosquamous conditions | | |
| Lichen planus | 2 | 0 |
| Pityriasis rosea | 3 | 0 |
| Photosensitivity and photodermatosis conditions | | |
| Photosensitivity reaction | 2 | 0 |
| Pilar disorders NEC | | |
| Piloerection | 1 | 0 |
| Pruritus NEC | | |
| Pruritus | 76 | 0 |
| Psoriatic conditions | | |
| Psoriasis | 12 | 0 |
| Purpura and related conditions | | |
| Petechiae | 1 | 0 |
| Rashes, eruptions and exanthems NEC | | |
| Rash | 85 | 0 |
| Rash erythematous | 21 | 0 |
| Rash macular | 6 | 0 |
| Rash morbilliform | 1 | 0 |
| Rash papular | 3 | 0 |
| Rash pruritic | 25 | 0 |
| Systemic lupus erythematosus rash | 1 | 0 |
| Skin vasculitides | | |
| Vasculitic rash | 2 | 0 |
| Urticarias | | |
| Chronic spontaneous urticaria | 1 | 0 |
| Cold urticaria | 1 | 0 |
| Mechanical urticaria | 1 | 0 |
| Urticaria | 27 | 0 |
| Urticaria chronic | 1 | 0 |
| Skin disorders SOC TOTAL | 428 | 0 |

Name: FOI 24/307 All Yellow Card reports for COVID-19 Pfizer-BioNTech vaccine (Batch EN1185)

Report Run Date: 23-Apr-2024 Data Lock Date: 22-Apr-2024 18:30:03
Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1

| Reaction Name | Total | Fatal |
|---|-------|-------|
| Social circumstances | | |
| Age related issues | | |
| Infant | 1 | 0 |
| Menopause | 1 | 0 |
| Disability issues | | |
| Loss of personal independence in daily activities | 1 | 0 |
| Sight disability | 1 | 0 |
| Social circumstances SOC TOTAL | 4 | 0 |

Name: FOI 24/307 All Yellow Card reports for COVID-19 Pfizer-BioNTech vaccine (Batch EN1185)

Report Run Date: 23-Apr-2024 Data Lock Date: 22-Apr-2024 18:30:03
Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1

| Reaction Name | Total | Fatal |
|---|-------|-------|
| Surgical & medical procedures | | |
| Immunisations | | |
| COVID-19 immunisation | 1 | 0 |
| Therapeutic procedures NEC | | |
| Injection | 2 | 0 |
| Tracheal therapeutic procedures | | |
| Tracheostomy | 1 | 0 |
| Surgical & medical procedures SOC TOTAL | 4 | 0 |

Name: FOI 24/307 All Yellow Card reports for COVID-19 Pfizer-BioNTech vaccine (Batch EN1185)

Report Run Date: 23-Apr-2024 Data Lock Date: 22-Apr-2024 18:30:03
Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1

| Earliest Reaction Date: 16-Feb-2001 MedDRA Version: MedDRA 26.1 | | |
|--|---------------|--------------|
| Reaction Name | <u> Total</u> | <u>Fatal</u> |
| Vascular disorders | | |
| Circulatory collapse and shock | | |
| Circulatory collapse | 1 | 0 |
| Haemorrhages NEC | | |
| Haematoma | 1 | 0 |
| Haemorrhage | 6 | 0 |
| Internal haemorrhage | 1 | O |
| Lymphoedemas | | |
| Lymphoedema | 2 | O |
| Non-site specific embolism and thrombosis | | |
| Embolism | 1 | O |
| Thrombosis | 6 | 0 |
| Venous thrombosis | 1 | 0 |
| Peripheral embolism and thrombosis | | |
| Deep vein thrombosis | 9 | 0 |
| Femoral artery embolism | 1 | 0 |
| Peripheral vascular disorders NEC | | |
| Flushing | 10 | 0 |
| Hot flush | 16 | O |
| Peripheral vasoconstriction, necrosis and vascular insufficiency | | |
| Peripheral coldness | 7 | 0 |
| Peripheral ischaemia | 2 | O |
| Phlebitis NEC | | |
| Phlebitis | 4 | 0 |
| Site specific vascular disorders NEC | | |
| Pallor | 4 | 0 |
| Varicose veins NEC | | |
| Varicose vein | 1 | 0 |
| Vascular hypertensive disorders NEC | | |
| Essential hypertension | 1 | 0 |
| Hypertension | 14 | 0 |
| Vascular hypotensive disorders | | |
| Diastolic hypotension | 1 | 0 |
| Hypotension | 4 | 0 |
| Orthostatic hypotension | 1 | 0 |
| Vasculitides NEC | | |
| Vasculitis | 1 | 0 |
| Vascular disorders SOC TOTAL | 95 | 0 |
| TOTAL REACTIONS FOR DRUG | 5080 | |
| | | |
| TOTAL REPORTS | 1745 | |
| TOTAL REPORTS TOTAL FATAL OUTCOME REPORTS | 1743 | 7 |
| IOTALI ATAL OUTOOME REPORTS | | |